Nature Communications (Jul 2020)

Molecular engineering of safe and efficacious oral basal insulin

  • Frantisek Hubálek,
  • Hanne H. F. Refsgaard,
  • Sanne Gram-Nielsen,
  • Peter Madsen,
  • Erica Nishimura,
  • Martin Münzel,
  • Christian Lehn Brand,
  • Carsten Enggaard Stidsen,
  • Christian Hove Claussen,
  • Erik Max Wulff,
  • Lone Pridal,
  • Ulla Ribel,
  • Jonas Kildegaard,
  • Trine Porsgaard,
  • Eva Johansson,
  • Dorte Bjerre Steensgaard,
  • Lars Hovgaard,
  • Tine Glendorf,
  • Bo Falck Hansen,
  • Maja Kirkegaard Jensen,
  • Peter Kresten Nielsen,
  • Svend Ludvigsen,
  • Susanne Rugh,
  • Patrick W. Garibay,
  • Mary Courtney Moore,
  • Alan D. Cherrington,
  • Thomas Kjeldsen

DOI
https://doi.org/10.1038/s41467-020-17487-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 9

Abstract

Read online

Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.